Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

NCT07167329 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Von Hippel Lindau
Von Hippel Lindau Disease
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Hemangioblastoma (HB) of the Central Nervous System (CNS)
PNET
Retinal Angiomatous Proliferation
Pheochromocytoma/Paraganglioma
Endolymphatic Sac Tumor

Interventions

DRUG: Belzutifan

Sponsor

José Claudio Casali da Rocha

Collaborators

[object Object]